Spectrum Pharmaceuticals, Inc. (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, announced it has entered into a five-year debt financing agreement with investment affiliates managed by SLR Capital Partners, LLC for a term loan facility of up to US$65 million. Under the terms of the agreement, Spectrum will have access to up to US$65 million in debt financing, divided into four tranches, the first of which was a US$30 million loan drawn upon closing on September 21, 2022. The remaining US$35 million will be made available in three additional tranches subject to the achievement of pre-specified regulatory and financial milestones.
Latham & Watkins LLP represented Spectrum Pharmaceuticals in the deal with a finance team led by Bay Area partner Haim Zaltzman, with Houston associates Benjamin Gelfand and Whitley Johnson. Advice was also provided on corporate matters by San Diego partner Teri O’Brien and New York partner Reza Mojtabee-Zamani, with New York associate Eric Rice; on tax matters by Los Angeles partner Eric Cho; on FDA regulatory matters by Washington, D.C. partner Ben Haas, with Washington, D.C. associate Meryl Bartlett; and on healthcare regulatory matters by Bay Area counsel Betty Pang.
Where the legal industry reads first.
Enjoyed this article? Get the biggest legal industry updates, deals, appointments, insights and expert interviews in your inbox, free.
No spam. Unsubscribe anytime.From Legal Desire
Is your firm the one being cited, or the one being skipped?
We ran the test. On several everyday legal questions, software companies are answering and law firms are not. We help firms fix that, and we build the technology behind the practice.
The advising firms, the named deal team, the value and the parties, with every other announced deal by the same firms and lawyers. Open the deal record
